Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABSI

ABSI - Absci Corporation Stock Price, Fair Value and News

4.88USD+0.07 (+1.46%)Delayed as of 21 Feb 2024, 01:01 pm ET
Watchlist

Market Summary

USD4.88+0.07
Delayedas of 21 Feb 2024, 01:01 pm
1.46%

ABSI Stock Price

View Fullscreen

ABSI RSI Chart

ABSI Valuation

Market Cap

447.0M

Price/Earnings (Trailing)

-4.2

Price/Sales (Trailing)

64.44

EV/EBITDA

-4.11

Price/Free Cashflow

-6.42

ABSI Price/Sales (Trailing)

ABSI Profitability

EBT Margin

-1541.59%

Return on Equity

-54.22%

Return on Assets

-45.06%

Free Cashflow Yield

-15.59%

ABSI Fundamentals

ABSI Revenue

Revenue (TTM)

6.9M

Rev. Growth (Yr)

-68.59%

Rev. Growth (Qtr)

-77.9%

ABSI Earnings

Earnings (TTM)

-106.5M

Earnings Growth (Yr)

19.31%

Earnings Growth (Qtr)

47.22%

Breaking Down ABSI Revenue

52 Week Range

1.134.94
(Low)(High)

Last 7 days

24.0%

Last 30 days

33.6%

Last 90 days

267.6%

Trailing 12 Months

103.8%

How does ABSI drawdown profile look like?

ABSI Financial Health

Current Ratio

4.82

ABSI Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20236.2M8.6M6.9M0
20224.7M4.7M5.5M5.7M
20214.8M4.9M4.9M4.9M
20200004.8M

Tracking the Latest Insider Buys and Sells of Absci Corporation

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
busch andreas
acquired
-
-
83,125
chief innovation officer
Feb 01, 2024
bedrick todd
acquired
-
-
20,570
svp, cao
Feb 01, 2024
jonasson zachariah
acquired
-
-
114,010
cfo / cbo
Feb 01, 2024
mcclain sean
acquired
-
-
182,000
chief executive officer
Nov 28, 2023
phoenix venture partners ii lp
sold
-58,248
1.4404
-40,439
-
Nov 27, 2023
phoenix venture partners ii lp
sold
-18,165
1.4018
-12,959
-
Nov 24, 2023
phoenix venture partners ii lp
sold
-15,326
1.4219
-10,779
-
Nov 22, 2023
phoenix venture partners ii lp
sold
-4,927
1.4047
-3,508
-
Nov 21, 2023
phoenix venture partners ii lp
sold
-1,736
1.404
-1,237
-
Nov 20, 2023
phoenix venture partners ii lp
sold
-34,811
1.4285
-24,369
-

1–10 of 35

Which funds bought or sold ABSI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
reduced
-50.00
-
-
-%
Feb 15, 2024
Farther Finance Advisors, LLC
reduced
-93.97
-525,437
124,744
0.01%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
1,028,270
1,028,270
-%
Feb 14, 2024
MOORE CAPITAL MANAGEMENT, LP
sold off
-100
-132,000
-
-%
Feb 14, 2024
Verition Fund Management LLC
sold off
-100
-46,728
-
-%
Feb 14, 2024
Casdin Capital, LLC
unchanged
-
2,802,990
4,087,690
0.40%
Feb 14, 2024
Squarepoint Ops LLC
reduced
-53.65
144,235
448,094
-%
Feb 14, 2024
Point72 Asia (Singapore) Pte. Ltd.
new
-
63,134
63,134
0.01%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
new
-
70,736
70,736
-%
Feb 14, 2024
Cubist Systematic Strategies, LLC
added
23.77
205,205
275,045
-%

1–10 of 42

Are Funds Buying or Selling ABSI?

Are funds buying ABSI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABSI
No. of Funds

Unveiling Absci Corporation's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
phoenix venture partners ii lp
15.5%
14,379,522
SC 13G/A
Feb 13, 2024
mcclain sean
10.0%
9,373,113
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
May 08, 2023
casdin capital, llc
4.8%
4,448,260
SC 13D/A
Mar 20, 2023
casdin capital, llc
6.%
5,533,260
SC 13D/A
Feb 14, 2023
phoenix venture partners ii lp
15.7%
14,492,813
SC 13G/A
Feb 14, 2023
mcclain sean
9.8%
9,083,128
SC 13G/A
Feb 13, 2023
casdin capital, llc
7.0%
6,473,260
SC 13D/A
Feb 13, 2023
absci corp
9.8%
9,083,128
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Absci Corporation

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
5
Insider Trading
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Jan 08, 2024
8-K
Current Report
Jan 04, 2024
4
Insider Trading

Peers (Alternatives to Absci Corporation)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Absci Corporation News

Latest updates
Seeking Alpha6 hours ago
InvestorsObserver16 Feb 202401:09 pm
MarketBeat13 Feb 202408:33 am
InvestorsObserver03 Jan 202408:00 am
Seeking Alpha26 Dec 202308:00 am

Absci Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue-77.9%744,0003,367,0001,269,0001,557,0002,369,0001,002,000819,0001,292,5001,539,0001,047,0001,063,000989,500916,000
Operating Expenses-48.1%24,047,00046,355,00025,754,00022,650,00030,336,00029,889,00029,622,00027,708,00022,681,00017,420,00012,211,000-4,280,000
  S&GA Expenses1.0%9,505,0009,410,0009,593,0007,749,00011,407,00010,507,00010,889,0009,183,0009,733,0005,179,0004,685,000-1,257,000
  R&D Expenses-8.9%11,029,00012,112,00012,657,00011,315,00015,525,00016,241,00015,827,00015,766,00010,730,00011,040,0007,050,000-2,692,000
EBITDA Margin-16.2%-13.23-11.38-13.73-15.90-17.98-20.86-24.49-20.19-2.57-2.59-2.61-2.63-
Interest Expenses-10.5%229,000256,000321,000287,000279,000211,000195,000200,000768,0002,009,000455,000-172,000
Income Taxes209.1%34,00011,0007,000-500,000-312,000-270,000621,000-1,090,500-1,703,000-5,617,000-500,000--
Earnings Before Taxes47.3%-21,960,000-41,661,000-23,348,000-19,971,000-27,571,000-28,950,000-28,873,000-26,268,000-25,337,000-46,815,000-11,439,000--3,748,000
EBT Margin-17.3%-15.42-13.15-16.11-18.33-20.37-23.52-27.10-22.23-2.93-2.95-2.98-3.00-
Net Income47.2%-21,994,000-41,672,000-23,355,000-19,471,000-27,259,000-28,680,000-29,494,000-25,166,000-23,634,000-41,198,000-10,962,000-4,939,000-3,748,000
Net Income Margin-17.6%-15.35-13.05-15.94-18.25-20.17-22.99-25.44-20.43-16.47-12.52-4.70-3.00-
Free Cashflow45.3%-10,668,000-19,490,000-20,399,000-19,128,000-23,913,000-26,467,000-28,006,000-25,395,000-27,367,000-32,234,000-13,649,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-7.0%23625429632133936639542644925717389.00
  Current Assets-9.0%135148165187201228256273301112-73.00
    Cash Equivalents14.2%70.0061.0011.0060.0012422325128030712718572.00
  Goodwill---21.0021.0021.0021.0021.0021.0023.0023.00--
Liabilities3.0%40.0039.0042.0047.0046.0050.0055.0060.0061.0022012122.00
  Current Liabilities9.8%28.0025.0027.0030.0030.0032.0042.0034.0030.0030.00-10.00
Shareholder's Equity-8.8%19621525427429331634036638818.003.001.00
  Retained Earnings-6.1%-382-360-319-295-276-249-220-191-165-142--90.06
  Additional Paid-In Capital0.5%57957657357056956556155755418.00-1.00
Shares Outstanding0.4%93.0093.0092.0092.0093.0090.0090.0093.0036.0017.0017.0018.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations46.1%-10,361-19,234-20,119-18,568-19,043-22,579-21,149-17,079-21,747-14,487-7,285---
  Share Based Compensation-16.3%2,5443,0412,6521,0243,5674,2093,7403,2323,7831,4412,152---
Cashflow From Investing-71.3%20,13570,152-27,301-30,179-78,723-11,223-6,857-8,316-6,820-43,365-8,876---
Cashflow From Financing24.3%-924-1,220-1,1041,393-9215,823-1,058-1,296208,387-474129,576---

ABSI Income Statement

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Technology development revenue$ 744$ 2,004$ 5,380$ 3,094
Collaboration revenue036501,096
Total revenues7442,3695,3804,190
Operating expenses    
Research and development11,02915,52535,79847,593
Selling, general and administrative9,50511,40728,50832,803
Depreciation and amortization3,5133,40410,5159,451
Goodwill impairment0021,3350
Total operating expenses24,04730,33696,15689,847
Operating loss(23,303)(27,967)(90,776)(85,657)
Other income (expense)    
Interest expense(229)(279)(806)(685)
Other income, net1,5726754,613948
Total other income (expense), net1,3433963,807263
Loss before income taxes(21,960)(27,571)(86,969)(85,394)
Income tax (expense) benefit(34)312(52)(39)
Net loss$ (21,994)$ (27,259)$ (87,021)$ (85,433)
Net loss per share: basic (in usd per share)$ (0.24)$ (0.30)$ (0.95)$ (0.94)
Net loss per share: diluted (in usd per share)$ (0.24)$ (0.30)$ (0.95)$ (0.94)
Weighted-average common shares outstanding: basic (in shares)92,217,23491,105,26591,844,22190,686,517
Weighted-average common shares outstanding: diluted (in shares)92,217,23491,105,26591,844,22190,686,517
Comprehensive loss:    
Net loss$ (21,994)$ (27,259)$ (87,021)$ (85,433)
Foreign currency translation adjustments78(27)22(77)
Unrealized gain on investments911439116
Comprehensive loss$ (21,907)$ (27,172)$ (86,960)$ (85,394)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]  License and Service [Member] 

ABSI Balance Sheet

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 69,733$ 59,955
Restricted cash16,03515,023
Short-term investments43,746104,476
Receivables under development arrangements, net8001,550
Prepaid expenses and other current assets4,3995,859
Total current assets134,713186,863
Operating lease right-of-use assets4,6885,319
Property and equipment, net45,21352,723
Intangibles, net49,09551,622
Goodwill021,335
Restricted cash, long-term1,0981,864
Other long-term assets1,5371,282
TOTAL ASSETS236,344321,008
Current liabilities:  
Accounts payable1,9092,412
Accrued expenses19,67720,481
Long-term debt3,2132,946
Operating lease obligations1,7461,690
Financing lease obligations1,0832,296
Deferred revenue345445
Total current liabilities27,97330,270
Long-term debt - net of current portion5,5497,984
Operating lease obligations - net of current portion5,9957,317
Finance lease obligations - net of current portion162750
Deferred tax, net249238
Other long-term liabilities035
TOTAL LIABILITIES39,92846,594
Commitments (See Note 8)
STOCKHOLDERS' EQUITY  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 92,936,980 and 92,411,103 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively99
Additional paid-in capital579,416570,454
Accumulated deficit(382,950)(295,929)
Accumulated other comprehensive loss(59)(120)
TOTAL STOCKHOLDERS' EQUITY196,416274,414
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 236,344$ 321,008
ABSI
Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington.
 CEO
 WEBSITEwww.absci.com
 EMPLOYEES193

Absci Corporation Frequently Asked Questions


What is the ticker symbol for Absci Corporation? What does ABSI stand for in stocks?

ABSI is the stock ticker symbol of Absci Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Absci Corporation (ABSI)?

As of Tue Feb 20 2024, market cap of Absci Corporation is 447.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABSI stock?

You can check ABSI's fair value in chart for subscribers.

What is the fair value of ABSI stock?

You can check ABSI's fair value in chart for subscribers. The fair value of Absci Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Absci Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABSI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Absci Corporation a good stock to buy?

The fair value guage provides a quick view whether ABSI is over valued or under valued. Whether Absci Corporation is cheap or expensive depends on the assumptions which impact Absci Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABSI.

What is Absci Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, ABSI's PE ratio (Price to Earnings) is -4.2 and Price to Sales (PS) ratio is 64.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABSI PE ratio will change depending on the future growth rate expectations of investors.